CN
CN
|
3SBio Group has always been committed to solving the problem of clinical drug use for patients, constantly conquering the challenges of the disease, using high-quality drugs to improve the quality of life of patients, and working hard for the benefit of human health. |
An exclusive license agreement to develop and market Leukotuxima in China and 13 other countries
Exclusive import, production and distribution rights for all voclosporin transplantation and autoimmune related indications in China
Exclusive license agreement to develop, manufacture and market tanibirumab in Greater China (including Hong Kong, Macau and Taiwan), Thailand, Russia and Brazil
Be authorized to develop and conduct clinical trials to obtain approval from the Food and Drug Administration for anti-tumor necrosis factor α, and authorized to manufacture, sell, promote and distribute humanized anti-human TNFα monoclonal antibodies in China
Acquired development, production and distribution rights for all pegsiscase indications in the world (excluding Taiwan)
Awarded exclusive distribution rights to the US biopharmaceutical company SelectaBiosciences to develop and market pegsiticase globally (except China, Hong Kong, Macau, Taiwan and Japan)
Exclusive license agreement to develop and market Bcl-2/xL inhibitors and IAP inhibitors
Exclusive license agreement to develop, produce and market pegylated irinotecan
Chengchuang will obtain the clinical trial approval for Colestilan and will transfer the relevant approval to us. We will then conduct clinical trials and apply for the production of Colestilan